title: Lenalidomide with dexamethasone treatment for relapsed/refractory myeloma patients in Korea-experience from 110 patients.
abstract: We conducted a retrospective analysis of lenalidomide with dexamethasone for patients with relapsed/refractory multiple myeloma (RRMM) who were treated within the Korean patient access program. Lenalidomide has been approved for RRMM for several years in Europe and North America, but has not been accessible to Asian patients in the past. Between 2008 and 2012, 110 patients from 20 hospitals were enrolled. The overall response rate (ORR) was 43.6 % with 15.4 % of very good partial response (VGPR) or better. The median time to progression (TTP) in this heavily pretreated patient population was 8.0 months, and median overall survival (OS) was 23 months. Hematologic toxicities, fatigue, anorexia, and constipation were the most common adverse events. The number of previous treatment lines, previous exposure to thalidomide, refractoriness to thalidomide and bortezomib, pretreatment white blood cell count (WBC), platelet count, t(14;16), and 17p deletion were significant prognostic factors for TTP, and creatinine clearance, refractoriness to thalidomide and bortezomib, performance status, platelet count, and 17p deletion were significant for OS in univariate analysis. In multivariate analysis, WBC and platelet count were significant prognostic factors for TTP and performance status for OS. For Korean myeloma patients, lenalidomide showed considerable efficacy, and toxicities were comparable to the data published in Europe and North America.
authors.affiliation: Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Irwon-dong, Gangnam-gu, Seoul, 135-710, South Korea, kihyunkimk@gmail.com.
authors.forename: Kihyun
authors.initials: K
authors.lastname: Kim
authors.forename: Seok Jin
authors.initials: SJ
authors.lastname: Kim
authors.forename: Verena
authors.initials: V
authors.lastname: Voelter
authors.forename: Cheolwon
authors.initials: C
authors.lastname: Suh
authors.forename: Sung-Soo
authors.initials: SS
authors.lastname: Yoon
authors.forename: Je-Jung
authors.initials: JJ
authors.lastname: Lee
authors.forename: Jae-Yong
authors.initials: JY
authors.lastname: Kwak
authors.forename: Hun-Mo
authors.initials: HM
authors.lastname: Ryoo
authors.forename: Yang Soo
authors.initials: YS
authors.lastname: Kim
authors.forename: Joon Ho
authors.initials: JH
authors.lastname: Moon
authors.forename: Seong Kyu
authors.initials: SK
authors.lastname: Park
authors.forename: Sung-Hyun
authors.initials: SH
authors.lastname: Kim
authors.forename: Yeung-Chul
authors.initials: YC
authors.lastname: Mun
authors.forename: Jin Seok
authors.initials: JS
authors.lastname: Kim
authors.forename: Hyeon-Seok
authors.initials: HS
authors.lastname: Eom
authors.forename: Deog-Yeon
authors.initials: DY
authors.lastname: Jo
authors.forename: Hyun Jung
authors.initials: HJ
authors.lastname: Jun
authors.forename: Ki-Hwan
authors.initials: KH
authors.lastname: Kim
authors.forename: Jeong-Ok
authors.initials: JO
authors.lastname: Lee
authors.forename: Jae Hoon
authors.initials: JH
authors.lastname: Lee
authors.forename: Chang-Ki
authors.initials: CK
authors.lastname: Min
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001897:Boronic Acids / Q000494:pharmacology; D000069286:Bortezomib; D002869:Chromosome Aberrations; D003131:Combined Modality Therapy; D003907:Dexamethasone / Q000008:administration & dosage / Q000009:adverse effects; D018572:Disease-Free Survival; D004341:Drug Evaluation; D019008:Drug Resistance, Neoplasm; D005221:Fatigue / Q000139:chemically induced; D005260:Female; D005500:Follow-Up Studies; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006402:Hematologic Diseases / Q000139:chemically induced; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D053208:Kaplan-Meier Estimate; D007723:Korea; D000077269:Lenalidomide; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000235:genetics / Q000601:surgery; D011719:Pyrazines / Q000494:pharmacology; D012189:Retrospective Studies; D013792:Thalidomide / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives / Q000494:pharmacology; D016896:Treatment Outcome
chemical_list: D001897:Boronic Acids; D011719:Pyrazines; D013792:Thalidomide; D000069286:Bortezomib; D003907:Dexamethasone; D000077269:Lenalidomide